Literature DB >> 10719363

Isolation and characterization of a novel TP53-inducible gene, TP53TG5, which suppresses growth and shows cell cycle-dependent transition of expression.

S Isaka1, Y Takei, T Tokino, K Koyama, Y Miyoshi, M Suzuki, E Takahashi, C Azuma, Y Murata, Y Nakamura.   

Abstract

Through a strategy of direct cloning of TP53-binding DNA sequences from human genome DNA, we have identified a novel TP53-target gene, termed TP53TG5 (TP53-target gene 5). This gene, localized to chromosome band 20q13.1 by fluorescence in situ hybridization, encodes a 290-amino-acid peptide with no significant homology with any known proteins in the public database. A colony-formation assay using human glioblastoma cell line T98G, which lacks wild-type TP53 and expresses no endogenous TP53TG5, revealed a growth-suppressive effect of the TP53TG5 gene product. Furthermore, immunohistochemical studies, following transfection of T98G with plasmid designed to express green fluorescent protein-fused TP53TG5, revealed cell cycle-dependent intracellular localization of this protein. Our results suggest that functional studies of TP53TG5 may provide new insights into the complex physiological activities of TP53. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719363     DOI: 10.1002/(sici)1098-2264(200004)27:4<345::aid-gcc2>3.0.co;2-3

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  2 in total

1.  Calreticulin mediates an invasive breast cancer phenotype through the transcriptional dysregulation of p53 and MAPK pathways.

Authors:  Mohammadreza Zamanian; Lama Abdel Qader Hamadneh; Abhi Veerakumarasivam; Sabariah Abdul Rahman; Shamarina Shohaimi; Rozita Rosli
Journal:  Cancer Cell Int       Date:  2016-07-13       Impact factor: 5.722

2.  Apoptosis-related gene expression can predict the response of ovarian cancer cell lines to treatment with recombinant human TRAIL alone or combined with cisplatin.

Authors:  Letícia da Conceição Braga; Nikole Gontijo Gonçales; Rafaela de Souza Furtado; Warne Pedro de Andrade; Luciana Maria Silva; Agnaldo Lopes da Silva Filho
Journal:  Clinics (Sao Paulo)       Date:  2020-03-13       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.